Hepatic Encephalopathy - Pipeline Review, H1 2017

Publisher Name :
Date: 28-Feb-2017
No. of pages: 52
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H1 2017, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic Encephalopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 1, 1, 4 and 1 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).

  • The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Hepatic Encephalopathy - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatic Encephalopathy - Overview
Hepatic Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hepatic Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatic Encephalopathy - Companies Involved in Therapeutics Development
Cosmo Pharmaceuticals NV
KannaLife Sciences Inc
Ocera Therapeutics Inc
Rebiotix Inc
Spherium Biomed SL
Umecrine Cognition AB
Versantis AG
Hepatic Encephalopathy - Drug Profiles
GR-3027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBX-2477 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THDP-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatic Encephalopathy - Dormant Projects
Hepatic Encephalopathy - Discontinued Products
Hepatic Encephalopathy - Product Development Milestones
Featured News & Press Releases
Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
Dec 07, 2016: Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
Nov 03, 2016: Karolinska Development company Umecrine Cognition announces positive Phase 1 data with GR3027 in hepatic encephalopathy
Nov 02, 2016: Ocera Therapeutics: Update on OCR-002
Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)
Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027
Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy
Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy
Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019
Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Hepatic Encephalopathy, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
Hepatic Encephalopathy - Pipeline by KannaLife Sciences Inc, H1 2017
Hepatic Encephalopathy - Pipeline by Ocera Therapeutics Inc, H1 2017
Hepatic Encephalopathy - Pipeline by Rebiotix Inc, H1 2017
Hepatic Encephalopathy - Pipeline by Spherium Biomed SL, H1 2017
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H1 2017
Hepatic Encephalopathy - Pipeline by Versantis AG, H1 2017
Hepatic Encephalopathy - Dormant Projects, H1 2017
Hepatic Encephalopathy - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Hepatic Encephalopathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • 2018-2023 Global Acute Ischemic Stroke Therapeutics Consumption Market Report
    Published: 22-Aug-2018        Price: US 4660 Onwards        Pages: 133
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Acute Ischemic Stroke Therapeutics market for 2018-2023. AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics m......
  • Global and India Varicose Vein Treatment Market Research by Company, Type & Application 2013-2025
    Published: 19-Aug-2018        Price: US 2000 Onwards        Pages: 89
    Summary There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. Market Segment as follows: By Type - Laser Varicose Vein Treatment - Radiofrequency Varicose Vein Treatment......
  • Global and India Brachytherapy Afterloader Seeds Market Research by Company, Type & Application 2013-2025
    Published: 18-Aug-2018        Price: US 2000 Onwards        Pages: 92
    Summary Brachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, and skin cancer and can also be used to treat tumors in many other body sites.Brachytherapy Afterloaders, is kind of machine used in brachytherapy to delivere......
  • Global Infantile Spasms Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 17-Aug-2018        Price: US 3480 Onwards        Pages: 132
    An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with s......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Infantile Spasms Therapeutics Market 2018, Forecast to 2023
    Published: 17-Aug-2018        Price: US 4880 Onwards        Pages: 137
    An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with s......
  • Global Enzyme Replacement Therapy Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 17-Aug-2018        Price: US 3480 Onwards        Pages: 133
    Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme. Scope of the Report: This report studies the Enzyme Replacement Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global mar......
  • Global Clostridium Difficile Treatment Market Data Survey Report 2025
    Published: 06-Aug-2018        Price: US 1500 Onwards        Pages: 75
    Summary The global Clostridium Difficile Treatment market will reach Volume Million USD in 2017 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Average market price by SUK Major applications Key manufacturers are included based on ......
  • Global Peptide Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 02-Aug-2018        Price: US 3480 Onwards        Pages: 145
    Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less. In this report, we study the peptide-based drugs. Scope of the Report: This report focuses on the Peptide Therapeut......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Peptide Therapeutics Market 2018, Forecast to 2023
    Published: 02-Aug-2018        Price: US 4880 Onwards        Pages: 147
    Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less. In this report, we study the peptide-based drugs. Scope of the Report: This report focuses on the Peptide Therapeut......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs